Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Myriad Genetics, Inc (NASDAQ: MYGN) closed the day trading at $7.84 up 0.90% from the previous closing price of $7.77. In other words, the price has increased by $0.90 from its previous closing price. On the day, 1.61 million shares were traded. MYGN stock price reached its highest trading level at $8.039 during the session, while it also had its lowest trading level at $7.675.
Ratios:
For a better understanding of MYGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.28 and its Current Ratio is at 1.42. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business. DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 729469888 and an Enterprise Value of 809669888. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.88 while its Price-to-Book (P/B) ratio in mrq is 1.88. Its current Enterprise Value per Revenue stands at 0.972 whereas that against EBITDA is -45.487.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.99, which has changed by -0.7047081 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $28.15, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is 34.95%, while the 200-Day Moving Average is calculated to be -8.24%.
Shares Statistics:
Over the past 3-months, MYGN traded about 1.75M shares per day on average, while over the past 10 days, MYGN traded about 1800620 shares per day. A total of 93.10M shares are outstanding, with a floating share count of 88.36M. Insiders hold about 5.04% of the company’s shares, while institutions hold 97.93% stake in the company. Shares short for MYGN as of 1756425600 were 8987945 with a Short Ratio of 5.15, compared to 1753920000 on 8498678. Therefore, it implies a Short% of Shares Outstanding of 8987945 and a Short% of Float of 13.58.
Earnings Estimates
Investors are keenly observing as 13.0 analysts analyze and rate the current performance of Myriad Genetics, Inc (MYGN) in the stock market.The consensus estimate for the next quarter is $0.0, with high estimates of $0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.02 and -$0.02 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.11, with 13.0 analysts recommending between $0.23 and -$0.02.
Revenue Estimates
12 analysts predict $205.26M in revenue for the current quarter. It ranges from a high estimate of $207.28M to a low estimate of $202.37M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $213.3MFor the next quarter, 12 analysts are estimating revenue of $208.29M. There is a high estimate of $211.8M for the next quarter, whereas the lowest estimate is $203.9M.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $826.43M, while the lowest revenue estimate was $818.1M, resulting in an average revenue estimate of $822.57M. In the same quarter a year ago, actual revenue was $837.6MBased on 13 analysts’ estimates, the company’s revenue will be $869.71M in the next fiscal year. The high estimate is $890.1M and the low estimate is $837M.
